Emma H. A. Stahlie

Emma H. A. Stahlie

Auto-generated profile, based on publicly available information

Emma H. A. Stahlie

Department of Surgical Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MRMaartje W. Rohaan
Maartje W. Rohaan
ESEmma H. A. Stahlie
Emma H. A. Stahlie
VFViola Franke
Viola Franke
LZLisanne P. Zijlker
Lisanne P. Zijlker
SWSofie Wilgenhof
Sofie Wilgenhof
JHJohn B. A. G. Haanen
John B. A. G. Haanen
Background: Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and pathologic response rates. Treatment with talimogene laherparepvec (T-VEC), a modified herpes simplex virus type-1 (HSV-1), is approved for patients with unresectable stage IIIB-IVM1a melanoma and has the potential to make tumors more susceptible for ICI. Combination ICI and intralesional T-VEC has already been investigated in patients with unresectable stage IIIB-IV disease, however, no data is available yet on the potential benefit of this combination therapy in neoadjuvant setting. Methods: This single center, single arm, phase II study aims to show an improved major pathologic complete response (pCR) rate, either pCR or near-pCR, up to 45% in 24 patients with resectable stage IIIB-IVM1a melanoma upon neoadjuvant combination treatment with intralesional T-VEC and systemic nivolumab (anti-PD-1 antibody). Patients will receive four courses of T-VEC up to 4 mL (first dose as seroconversion dose) and three doses of nivolumab (240 mg flatdose) every 2 weeks, followed by surgical resection in week nine. The primary endpoint of this trial is pathologic response rate. Secondary endpoints are safety, the rate of delay of surgery and event-free survival. Additionally, prognostic and predictive biomarker research and health-related quality of life evaluation will be performed. Discussion: Intralesional T-VEC has the capacity to heighten the immune response and to elicit an abscopal effect in melanoma in combination with ICI. However, the potential clinical benefit of T-VEC plus ICI in the neoadjuvant setting remains unknown. This is the first trial investigating the efficacy and safety of neoadjuvant treatment of T-VEC and nivolumab followed by surgical resection in patients with stage IIIB-IVM1a melanoma, with the potential of high pathologic response rates and acceptable toxicity. Trial registration: This trial was registered in the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT- number: 2019–001911-22) and the Central Committee on Research Involving Human Subjects (NL71866.000.19) on 4th June 2020. Secondary identifying number: NCT04330430.

28 January 2021 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
ESEmma H. A. Stahlie
Emma H. A. Stahlie
VFViola Franke
Viola Franke
CZCharlotte Zuur
Charlotte Zuur
WKWillem M. C. Klop
Willem M. C. Klop
BHBernies van der van der Hiel
Bernies van der van der Hiel
AAAlexander C.J. van Akkooi
Alexander C.J. van Akkooi

13 May 2022 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
ESEmma H.A. Stahlie
Emma H.A. Stahlie
EMEvalyn E.A.P. Mulder
Evalyn E.A.P. Mulder
SRSophie Reijers
Sophie Reijers
SBSara Balduzzi
Sara Balduzzi
CZCharlotte Zuur
Charlotte Zuur
AAAlexander C.J. van Akkooi
Alexander C.J. van Akkooi

1 May 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
ESE.H.A. Stahlie
E.H.A. Stahlie
BHB. van der Hiel
B. van der Hiel
ABA. Bruining
A. Bruining
BWB. van de Wiel
B. van de Wiel
YSY.M. Schrage
Y.M. Schrage
AAAlexander C.J. van Akkooi
Alexander C.J. van Akkooi

8 June 2022 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
RWRichard J. B. Walker
Richard J. B. Walker
NHNicole J. Look Hong
Nicole J. Look Hong
MMMarc D. Moncrieff
Marc D. Moncrieff
AAAlexander C. J. van Akkooi
Alexander C. J. van Akkooi
EJEvan Jost
Evan Jost
MMMichail N. Mavros
Michail N. Mavros

11 August 2020 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
ESEmma H. A. Stahlie
Emma H. A. Stahlie
BHBernies van der van der Hiel
Bernies van der van der Hiel
MSMarcel P. M. Stokkel
Marcel P. M. Stokkel
YSYvonne Schrage
Yvonne Schrage
WHWinan J. van Houdt
Winan J. van Houdt
AAAlexander C.J. van Akkooi
Alexander C.J. van Akkooi